FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-978-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$212.96 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen Inc (NASDAQ:FGEN) released its quarterly earnings results on Wednesday, February, 27th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.40. The biopharmaceutical company earned $108.05 million during the quarter, compared to analyst estimates of $72.15 million. FibroGen had a negative return on equity of 16.84% and a negative net margin of 40.58%. FibroGen's revenue for the quarter was up 251.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.27) EPS. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
4 Wall Street analysts have issued twelve-month price objectives for FibroGen's shares. Their forecasts range from $71.00 to $84.00. On average, they expect FibroGen's stock price to reach $75.00 in the next twelve months. This suggests a possible upside of 34.8% from the stock's current price. View Analyst Price Targets for FibroGen.
What is the consensus analysts' recommendation for FibroGen?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.
What are Wall Street analysts saying about FibroGen stock?
Here are some recent quotes from research analysts about FibroGen stock:
- 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (3/12/2019)
- 2. Mizuho analysts commented, "We believe efficacy data is likely to be a non-event in 4Q18. But we believe MACE will be share-moving. We believe roxadustat can achieve superiority vs. epoetin alfa in the DD patient population, given encouraging mortality rate observed in recent studies vs. much higher historical rates with epoetin alfa. In NDD, we believe the bar is higher (comparing to placebo) but showing non-inferiority is possible (more below)." (12/17/2018)
Has FibroGen been receiving favorable news coverage?
Media headlines about FGEN stock have trended somewhat positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. FibroGen earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Ionis Pharmaceuticals (IONS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of FibroGen own?
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
- Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)
- Dr. K. Peony Yu, Chief Medical Officer (Age 57)
- Mr. Julian N. Stern, Sec. (Age 94)
- Dr. Barry A. Berkowitz, Founder
When did FibroGen IPO?
(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Who are FibroGen's major shareholders?
FibroGen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (11.49%), BlackRock Inc. (7.42%), Hillhouse Capital Advisors Ltd. (2.36%), First Trust Advisors LP (2.01%), Eagle Asset Management Inc. (1.11%) and Northern Trust Corp (1.08%). Company insiders that own FibroGen stock include Gerald Lema, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Which major investors are selling FibroGen stock?
FGEN stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Millennium Management LLC, Candriam Luxembourg S.C.A., Prudential Financial Inc., MetLife Investment Advisors LLC, Eagle Asset Management Inc., Pinnacle Associates Ltd. and Principal Financial Group Inc.. Company insiders that have sold FibroGen company stock in the last year include James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff and Toshinari Tamura. View Insider Buying and Selling for FibroGen.
Which major investors are buying FibroGen stock?
FGEN stock was bought by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., FMR LLC, Norges Bank, Bank of New York Mellon Corp, Handelsbanken Fonder AB, D. E. Shaw & Co. Inc., Citigroup Inc. and Sofinnova Investments Inc.. View Insider Buying and Selling for FibroGen.
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $55.62.
How big of a company is FibroGen?
FibroGen has a market capitalization of $4.76 billion and generates $212.96 million in revenue each year. The biopharmaceutical company earns $-86,420,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis.
What is FibroGen's official website?
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
